Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 496 participants.

Also called NCT05041010

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 496 participants (planned count) (from the registry)
Sponsor
  • GNT Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05041010
Other papers using this trial's data
  • Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial JAMA network open, 2025-01-02 DOI, PubMed 39874036, PMC11775734 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05041010. Randomized; triple masking; primary purpose treatment. Start 2021-12-25 (actual); primary completion 2024-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Acronym
RODIN
Intervention (Drug)
Neu2000KWL group
Intervention (Drug)
Placebo group
Lead sponsor
GNT Pharma (class: industry)

Record details

Record id
cardio:ct-nct05041010
Content hash
2e4cb0b826db3134914671eb36f8b153a8c28e6ed726732c7e80aeb8133eb1b9